hydrochlorothiazide has been researched along with Albuminuria in 55 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In summary, among patients with DKD, amiloride could decrease albuminuria without severe side effects, which was accompanied by the significant decline of urinary suPAR." | 9.41 | The effect of amiloride in decreasing albuminuria in patients with diabetic kidney diseases: a prospective, crossover, open-label study. ( Chen, Y; Dong, W; Huang, Y; Li, R; Li, Z; Liang, H; Liang, X; Liu, S; Ma, J; Shi, W; Wang, W; Wu, Y; Xie, Z; Ye, Z; Zhang, L; Zhao, X, 2021) |
| "The present study failed to demonstrate the non-inferiority of the antialbuminuric effect of benidipine relative to that of hydrochlorothiazide in RAS inhibitor-treated hypertensive patients with macroalbuminuria." | 9.19 | Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in Renin-Angiotensin System (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics Tr ( Ando, K; Fujita, T; Isshiki, M; Kashihara, N; Nakanishi, T; Nangaku, M; Nishizawa, Y; Nitta, K; Rakugi, H; Shimosawa, T; Takahashi, K; Tomita, K; Yokoyama, H, 2014) |
| "The fixed irbesartan/hydrochlorothiazide combination may control blood pressure to the target level in about 60% of Chinese patients with moderate to severe hypertension, with an acceptable safety profile." | 9.17 | Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension. ( Dai, QY; Huang, QF; Li, Y; Ma, GS; Sheng, CS; Wang, JG, 2013) |
| "We examined blood pressure reduction and metabolic alterations after amlodipine/benazepril and valsartan/hydrochlorothiazide treatment in patients with type 2 diabetes mellitus and hypertension and microalbuminuria." | 9.16 | Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando ( Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012) |
| "CHILI T2D was a non-interventional, open-label, non-controlled, multicentre study in clinical practice that evaluated 4110 patients with type 2 diabetes, uncontrolled hypertension and microalbuminuria who were being prescribed a fixed-dose combination of candesartan cilexetil 16 mg/HCTZ 12." | 9.14 | Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study. ( Bramlage, P; Ketelhut, R, 2010) |
| "This study was conducted to determine the effects of a tablet combining losartan/hydrochlorothiazide (L/HCTZ) in comparison with losartan alone in Japanese diabetic patients with hypertension." | 9.14 | Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. ( Ichihara, A; Itoh, H; Kinouchi, K; Kurauchi-Mito, A; Sakoda, M, 2009) |
| "Patients with type 2 diabetes, mild-to-moderate hypertension (diastolic blood pressure 85-105 mmHg, systolic blood pressure <160 mmHg, and 24-hour mean systolic blood pressure >130 mmHg), and microalbuminuria were randomized to 1 year of doubleblind treatment with fixed-dose manidipine/delapril (n=54) or losartan/hydrochlorothiazide (HCTZ) (n=56)." | 9.14 | Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Wenzel, RR, 2009) |
| "We sought to compare the effect of manidipine versus hydrochlorothiazide (HCTZ) in addition to candesartan on the urinary albumin excretion rate (UAER) in hypertensive patients with type II diabetes and microalbuminuria." | 9.12 | Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. ( Corradi, L; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "The Angiotensin II Receptor Antagonist Micardis in Isolated Systolic hypertension (ARAMIS) study compared the antihypertensive efficacy after 6 weeks of once-daily fixed doses of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12." | 9.11 | The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. ( de Zeeuw, D; Köster, J; Manolis, AJ; Navis, G; Reid, JL; Vogt, L, 2005) |
| "At baseline, normoalbuminuria was found in 74 and 85 patients in the enalapril/hydrochlorothiazide and atenolol groups, respectively." | 9.08 | Combination of enalapril and low-dose thiazide reduces normoalbuminuria in essential hypertension. ( Dollerup, J; Mogensen, CE; Nielsen, B; Nielsen, S, 1998) |
| "Randomised, double blind, double dummy parallel study of normotensive diabetic patients with persistent microalbuminuria (30-300 mg/24 h) treated with enalapril or hydrochlorothiazide for one year after a three month, single blind placebo period." | 9.07 | Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes. ( Chatellier, G; Fressinaud, P; Gallois, Y; Hallab, M; Marre, M; Rohmer, V, 1993) |
| "We hypothesized that compared with hydrochlorothiazide (HCTZ), the renin inhibitor aliskiren (ALISK) or amlodipine (AMLO) and their combination reduce albuminuria via reduction in renal inflammation, independent of blood pressure (BP) changes." | 7.78 | Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats. ( Huang, J; Matavelli, LC; Siragy, HM, 2012) |
| "Studies were performed to determine if early treatment with an angiotensin II (Ang II) receptor blocker (ARB), olmesartan, prevents the onset of microalbuminuria by attenuating glomerular podocyte injury in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with type 2 diabetes mellitus." | 7.78 | Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. ( Hara, T; Hayden, MR; Hitomi, H; Ichimura, A; Ito, S; Kaifu, K; Kawachi, H; Kiyomoto, H; Kobori, H; Kohno, M; Matsumoto, S; Nishijima, Y; Nishiyama, A; Ohsaki, H; Sofue, T; Sowers, JR; Urushihara, M; Whaley-Connell, A, 2012) |
| "A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > or = 140 mmHg and/or diastolic blood pressure (DBP) > or = 90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study." | 6.70 | Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. ( Aznar, J; Llisterri, JL; Lozano, JV; Redon, J, 2001) |
| "Hydrochlorothiazide was then added for the subsequent 4 months." | 6.69 | Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. ( Half-Onn, E; Levi, Z; Rachmani, R; Ravid, M; Slavachevsky, I, 1998) |
| "In summary, among patients with DKD, amiloride could decrease albuminuria without severe side effects, which was accompanied by the significant decline of urinary suPAR." | 5.41 | The effect of amiloride in decreasing albuminuria in patients with diabetic kidney diseases: a prospective, crossover, open-label study. ( Chen, Y; Dong, W; Huang, Y; Li, R; Li, Z; Liang, H; Liang, X; Liu, S; Ma, J; Shi, W; Wang, W; Wu, Y; Xie, Z; Ye, Z; Zhang, L; Zhao, X, 2021) |
| " We aimed to investigate the effect of sodium restriction and the diuretic hydrochlorothiazide, separately and in combination, added to RAAS blockade on residual albuminuria in patients with type 2 diabetic nephropathy." | 5.19 | Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. ( Binnenmars, SH; Groen, H; Hemmelder, MH; Krikken, JA; Kwakernaak, AJ; Laverman, GD; Navis, G; Visser, FW; Woittiez, AJ, 2014) |
| "The present study failed to demonstrate the non-inferiority of the antialbuminuric effect of benidipine relative to that of hydrochlorothiazide in RAS inhibitor-treated hypertensive patients with macroalbuminuria." | 5.19 | Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in Renin-Angiotensin System (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics Tr ( Ando, K; Fujita, T; Isshiki, M; Kashihara, N; Nakanishi, T; Nangaku, M; Nishizawa, Y; Nitta, K; Rakugi, H; Shimosawa, T; Takahashi, K; Tomita, K; Yokoyama, H, 2014) |
| " The Morning Hypertension and Angiotensin Receptor Blocker/Hydrochlorothiazide Combination Therapy (MAPPY) study has shown that losartan/hydrochlorothiazide (HCTZ) combination is superior to high-dose losartan in not only reducing morning systolic blood pressure (SBP) but also ameliorating urinary albumin excretion (UAE) after 3-month treatment." | 5.17 | Reduction in morning blood pressure is a key factor for ameliorating urinary albumin excretion in patients with morning hypertension irrespective of treatment regimen. ( Adachi, H; Imaizumi, T; Kai, H; Kaneyuki, M; Kusaba, K; Mitsutake, Y; Shihara, M; Toyama, Y; Ueda, T; Umei, H, 2013) |
| "The fixed irbesartan/hydrochlorothiazide combination may control blood pressure to the target level in about 60% of Chinese patients with moderate to severe hypertension, with an acceptable safety profile." | 5.17 | Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension. ( Dai, QY; Huang, QF; Li, Y; Ma, GS; Sheng, CS; Wang, JG, 2013) |
| "We examined blood pressure reduction and metabolic alterations after amlodipine/benazepril and valsartan/hydrochlorothiazide treatment in patients with type 2 diabetes mellitus and hypertension and microalbuminuria." | 5.16 | Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando ( Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012) |
| "Patients with type 2 diabetes, mild-to-moderate hypertension (diastolic blood pressure 85-105 mmHg, systolic blood pressure <160 mmHg, and 24-hour mean systolic blood pressure >130 mmHg), and microalbuminuria were randomized to 1 year of doubleblind treatment with fixed-dose manidipine/delapril (n=54) or losartan/hydrochlorothiazide (HCTZ) (n=56)." | 5.14 | Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. ( Fogari, R; Kohlmann, O; Laurent, S; Roca-Cusachs, A; Schmieder, RE; Wenzel, RR, 2009) |
| "This study was conducted to determine the effects of a tablet combining losartan/hydrochlorothiazide (L/HCTZ) in comparison with losartan alone in Japanese diabetic patients with hypertension." | 5.14 | Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. ( Ichihara, A; Itoh, H; Kinouchi, K; Kurauchi-Mito, A; Sakoda, M, 2009) |
| " 11 506 patients with hypertension who were at high risk for cardiovascular events were randomly assigned via a central, telephone-based interactive voice response system in a 1:1 ratio to receive benazepril (20 mg) plus amlodipine (5 mg; n=5744) or benazepril (20 mg) plus hydrochlorothiazide (12." | 5.14 | Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. ( Bakris, GL; Chiang, YT; Dahlöf, B; Jamerson, K; Kelly, RY; Pitt, B; Sarafidis, PA; Shi, V; Staikos-Byrne, L; Velazquez, EJ; Weber, MA; Weir, MR, 2010) |
| "CHILI T2D was a non-interventional, open-label, non-controlled, multicentre study in clinical practice that evaluated 4110 patients with type 2 diabetes, uncontrolled hypertension and microalbuminuria who were being prescribed a fixed-dose combination of candesartan cilexetil 16 mg/HCTZ 12." | 5.14 | Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study. ( Bramlage, P; Ketelhut, R, 2010) |
| "We sought to compare the effect of manidipine versus hydrochlorothiazide (HCTZ) in addition to candesartan on the urinary albumin excretion rate (UAER) in hypertensive patients with type II diabetes and microalbuminuria." | 5.12 | Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. ( Corradi, L; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| " A new clinical trial, GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension), is designed to compare the change in urinary albumin to creatinine ratio after 1 year of initial treatment with either amlodipine besylate/benazepril HCl or benazepril HCl/hydrochlorothiazide." | 5.11 | Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. ( Bakris, GL; McCullough, PA; Toto, RD, 2005) |
| "The Angiotensin II Receptor Antagonist Micardis in Isolated Systolic hypertension (ARAMIS) study compared the antihypertensive efficacy after 6 weeks of once-daily fixed doses of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12." | 5.11 | The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. ( de Zeeuw, D; Köster, J; Manolis, AJ; Navis, G; Reid, JL; Vogt, L, 2005) |
| " Inclusion criteria were type 2 diabetes, hypertension > 140/90 mmHg and current treatment with irbesartan or irbesartan/hydrochlorothiazide (HTCZ)." | 5.11 | [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ]. ( Krekler, M; Schmieder, RE, 2005) |
| "To evaluate efficacy and tolerance of a compound drug co-renitec combining an ACE inhibitor enalapril maleate and diuretic hydrochlorothiazide co-renitec taken for 16 weeks in essential hypertension (EH)." | 5.10 | [Co-renitek treatment of patients with moderate and severe forms of hypertensive disease]. ( Chazova, IE; Dmitriev, VV; Khanbalaeva, MN; Kotkina, TI; Ratova, LG, 2003) |
| "5 mg of hydrochlorothiazide, in 90 type 2 diabetic patients with microalbuminuria and blood pressure > 130/85 mmHg, receiving losartan 50 mg as initial treatment during 4 weeks." | 5.10 | Losartan titration versus diuretic combination in type 2 diabetic patients. ( de Pablos-Velasco, PL; Esmatjes, JE; Fernandez-Vega, F; Lopez de la Torre, ML; Pazos Toral, F; Pozuelo, A; Ruilope, LM, 2002) |
| "The objectives of this study were to compare the effects of the angiotensin II receptor blocker, losartan, to those of the angiotensin-converting enzyme inhibitor, enalapril, on albuminuria and renal function in relationship to clinic and ambulatory blood pressure (ABP) in hypertensive type 2 diabetic subjects with early nephropathy." | 5.09 | Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. ( Bélanger, A; Godin, C; Hallé, JP; Lacourcière, Y; Marion, J; Ross, S; Wright, N, 2000) |
| "At baseline, normoalbuminuria was found in 74 and 85 patients in the enalapril/hydrochlorothiazide and atenolol groups, respectively." | 5.08 | Combination of enalapril and low-dose thiazide reduces normoalbuminuria in essential hypertension. ( Dollerup, J; Mogensen, CE; Nielsen, B; Nielsen, S, 1998) |
| "Randomised, double blind, double dummy parallel study of normotensive diabetic patients with persistent microalbuminuria (30-300 mg/24 h) treated with enalapril or hydrochlorothiazide for one year after a three month, single blind placebo period." | 5.07 | Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes. ( Chatellier, G; Fressinaud, P; Gallois, Y; Hallab, M; Marre, M; Rohmer, V, 1993) |
| "The effects of long-term treatment with captopril and conventional therapy on albuminuria and metabolic parameters were compared in 74 hypertensive type II diabetics with normal serum creatinine." | 5.07 | Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. ( Lacourcière, Y; Nadeau, A; Poirier, L; Tancrède, G, 1993) |
| "We have previously shown that an association of losartan and hydrochlorothiazide, initiated 1 mo after 5/6 nephrectomy (Nx), reversed hypertension and albuminuria and promoted lasting renoprotection." | 3.83 | An association of losartan-hydrochlorothiazide, but not losartan-furosemide, completely arrests progressive injury in the remnant kidney. ( Arias, SC; Fanelli, C; Fujihara, CK; Malheiros, DM; Souza, RA; Zatz, R, 2016) |
| "Adult patients with angiotensin receptor blocker (ARB)-resistant essential hypertension (n = 104) were enrolled and switched to combination therapy with losartan (50 mg/day) and hydrochlorothiazide (12." | 3.79 | Release from glomerular overload by the addition of low-dose thiazide in patients with angiotensin receptor blocker-resistant hypertension. ( Asakura, J; Hasegawa, H; Iwashita, T; Kawashima, K; Matsuda, A; Mitarai, T; Nakamura, T; Ogawa, T; Shimizu, T; Takayanagi, K; Tayama, Y, 2013) |
| "Studies were performed to determine if early treatment with an angiotensin II (Ang II) receptor blocker (ARB), olmesartan, prevents the onset of microalbuminuria by attenuating glomerular podocyte injury in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with type 2 diabetes mellitus." | 3.78 | Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. ( Hara, T; Hayden, MR; Hitomi, H; Ichimura, A; Ito, S; Kaifu, K; Kawachi, H; Kiyomoto, H; Kobori, H; Kohno, M; Matsumoto, S; Nishijima, Y; Nishiyama, A; Ohsaki, H; Sofue, T; Sowers, JR; Urushihara, M; Whaley-Connell, A, 2012) |
| "We hypothesized that compared with hydrochlorothiazide (HCTZ), the renin inhibitor aliskiren (ALISK) or amlodipine (AMLO) and their combination reduce albuminuria via reduction in renal inflammation, independent of blood pressure (BP) changes." | 3.78 | Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats. ( Huang, J; Matavelli, LC; Siragy, HM, 2012) |
| "We have compared the effects of the angiotensin converting enzyme inhibitor, perindopril, and a conventional antihypertensive regimen (triple therapy: hydralazine, reserpine and hydrochlorothiazide) on kidney function and albuminuria in hypertensive diabetic rats." | 3.68 | Antihypertensive therapy in a model combining spontaneous hypertension with diabetes. ( Allen, TJ; Cooper, ME; Doyle, AE; Jerums, G; O'Brien, RC; Rumble, JR, 1992) |
| "Seventy-six patients with type 2 diabetes and DKD (all with albuminuria and serum creatinine <1." | 2.78 | Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria. ( Gnudi, L; Hill, B; Karalliedde, J; Maltese, G; Viberti, G, 2013) |
| "Patients with high blood pressure are often overweight or even obese." | 2.71 | [Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice]. ( Bramlage, P; Kirch, W; Sharma, AM, 2004) |
| "A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > or = 140 mmHg and/or diastolic blood pressure (DBP) > or = 90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study." | 2.70 | Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. ( Aznar, J; Llisterri, JL; Lozano, JV; Redon, J, 2001) |
| "Hydrochlorothiazide was then added for the subsequent 4 months." | 2.69 | Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. ( Half-Onn, E; Levi, Z; Rachmani, R; Ravid, M; Slavachevsky, I, 1998) |
| "Perindopril was associated with significantly lower AER than lacidipine, whereas lacidipine was more potent in preventing increases in ocular AVC." | 1.29 | Organ specificity of antihypertensive therapy on ocular albumin vascular clearance and albuminuria in the hypertensive diabetic rat. ( Cooper, M; Gin, T; Jerums, G; Joon, TL; Panagiotopoulos, S; Taylor, H, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (23.64) | 18.2507 |
| 2000's | 23 (41.82) | 29.6817 |
| 2010's | 18 (32.73) | 24.3611 |
| 2020's | 1 (1.82) | 2.80 |
| Authors | Studies |
|---|---|
| Li, R | 1 |
| Xie, Z | 1 |
| Zhang, L | 1 |
| Huang, Y | 1 |
| Ma, J | 1 |
| Dong, W | 1 |
| Li, Z | 1 |
| Chen, Y | 1 |
| Liang, H | 1 |
| Wu, Y | 1 |
| Zhao, X | 1 |
| Wang, W | 1 |
| Ye, Z | 1 |
| Liu, S | 1 |
| Shi, W | 1 |
| Liang, X | 1 |
| Arias, SC | 2 |
| Valente, CP | 1 |
| Machado, FG | 1 |
| Fanelli, C | 2 |
| Origassa, CS | 1 |
| de Brito, T | 1 |
| Camara, NO | 1 |
| Malheiros, DM | 2 |
| Zatz, R | 2 |
| Fujihara, CK | 2 |
| Kai, H | 2 |
| Kaneyuki, M | 1 |
| Shihara, M | 1 |
| Toyama, Y | 1 |
| Mitsutake, Y | 1 |
| Umei, H | 1 |
| Kusaba, K | 1 |
| Ueda, T | 2 |
| Adachi, H | 1 |
| Imaizumi, T | 2 |
| Nishimura, H | 1 |
| Shintani, M | 1 |
| Maeda, K | 1 |
| Otoshi, K | 1 |
| Fukuda, M | 1 |
| Okuda, J | 1 |
| Nishi, S | 1 |
| Ohashi, S | 1 |
| Kato, S | 1 |
| Baba, Y | 1 |
| Huang, QF | 1 |
| Sheng, CS | 1 |
| Li, Y | 1 |
| Ma, GS | 1 |
| Dai, QY | 1 |
| Wang, JG | 1 |
| Karalliedde, J | 2 |
| Maltese, G | 1 |
| Hill, B | 1 |
| Viberti, G | 2 |
| Gnudi, L | 1 |
| Hasegawa, H | 1 |
| Tayama, Y | 1 |
| Takayanagi, K | 1 |
| Asakura, J | 1 |
| Nakamura, T | 1 |
| Kawashima, K | 1 |
| Shimizu, T | 1 |
| Iwashita, T | 1 |
| Ogawa, T | 1 |
| Matsuda, A | 1 |
| Mitarai, T | 1 |
| Fogari, R | 3 |
| Derosa, G | 1 |
| Zoppi, A | 2 |
| Lazzari, P | 2 |
| D'Angelo, A | 1 |
| Mugellini, A | 2 |
| Weir, MR | 2 |
| Kwakernaak, AJ | 1 |
| Krikken, JA | 1 |
| Binnenmars, SH | 1 |
| Visser, FW | 1 |
| Hemmelder, MH | 1 |
| Woittiez, AJ | 1 |
| Groen, H | 1 |
| Laverman, GD | 1 |
| Navis, G | 2 |
| Ando, K | 1 |
| Nitta, K | 1 |
| Rakugi, H | 1 |
| Nishizawa, Y | 1 |
| Yokoyama, H | 1 |
| Nakanishi, T | 1 |
| Kashihara, N | 1 |
| Tomita, K | 1 |
| Nangaku, M | 1 |
| Takahashi, K | 1 |
| Isshiki, M | 1 |
| Shimosawa, T | 1 |
| Fujita, T | 1 |
| Souza, RA | 1 |
| Kohlmann, O | 1 |
| Roca-Cusachs, A | 1 |
| Laurent, S | 1 |
| Schmieder, RE | 3 |
| Wenzel, RR | 1 |
| Ekinci, EI | 1 |
| Thomas, G | 1 |
| Thomas, D | 1 |
| Johnson, C | 1 |
| Macisaac, RJ | 1 |
| Houlihan, CA | 1 |
| Finch, S | 1 |
| Panagiotopoulos, S | 2 |
| O'Callaghan, C | 1 |
| Jerums, G | 3 |
| Kinouchi, K | 1 |
| Ichihara, A | 1 |
| Sakoda, M | 1 |
| Kurauchi-Mito, A | 1 |
| Itoh, H | 1 |
| Bakris, GL | 3 |
| Sarafidis, PA | 1 |
| Dahlöf, B | 1 |
| Pitt, B | 1 |
| Jamerson, K | 1 |
| Velazquez, EJ | 1 |
| Staikos-Byrne, L | 1 |
| Kelly, RY | 1 |
| Shi, V | 1 |
| Chiang, YT | 1 |
| Weber, MA | 1 |
| Ketelhut, R | 1 |
| Bramlage, P | 3 |
| Palatini, P | 1 |
| Matavelli, LC | 1 |
| Huang, J | 1 |
| Siragy, HM | 1 |
| Sofue, T | 1 |
| Kiyomoto, H | 1 |
| Kobori, H | 1 |
| Urushihara, M | 1 |
| Nishijima, Y | 1 |
| Kaifu, K | 1 |
| Hara, T | 1 |
| Matsumoto, S | 1 |
| Ichimura, A | 1 |
| Ohsaki, H | 1 |
| Hitomi, H | 1 |
| Kawachi, H | 1 |
| Hayden, MR | 1 |
| Whaley-Connell, A | 1 |
| Sowers, JR | 1 |
| Ito, S | 1 |
| Kohno, M | 1 |
| Nishiyama, A | 1 |
| Lee, IT | 1 |
| Hung, YJ | 1 |
| Chen, JF | 1 |
| Wang, CY | 1 |
| Lee, WJ | 1 |
| Sheu, WH | 1 |
| Chazova, IE | 1 |
| Ratova, LG | 1 |
| Dmitriev, VV | 1 |
| Khanbalaeva, MN | 1 |
| Kotkina, TI | 1 |
| Toto, RD | 2 |
| McCullough, PA | 2 |
| Lehnert, H | 1 |
| Pittrow, D | 1 |
| Kirch, W | 2 |
| Schram, MT | 1 |
| van Ittersum, FJ | 1 |
| Spoelstra-de Man, A | 1 |
| van Dijk, RA | 1 |
| Schalkwijk, CG | 1 |
| Ijzerman, RG | 1 |
| Twisk, JW | 1 |
| Stehouwer, CD | 1 |
| Krekler, M | 2 |
| Vogt, L | 1 |
| Köster, J | 1 |
| Manolis, AJ | 1 |
| Reid, JL | 1 |
| de Zeeuw, D | 1 |
| Kamgar, M | 1 |
| Nobakhthaghighi, N | 1 |
| Shamshirsaz, AA | 1 |
| Estacio, RO | 1 |
| McFann, KK | 1 |
| Schrier, RW | 1 |
| Sharma, AM | 1 |
| Tschöpe, C | 1 |
| Tschöpe, R | 1 |
| Unger, T | 1 |
| Joffe, HV | 1 |
| Kwong, RY | 1 |
| Gerhard-Herman, MD | 1 |
| Rice, C | 1 |
| Feldman, K | 1 |
| Adler, GK | 1 |
| Corradi, L | 1 |
| Preti, P | 1 |
| Rinaldi, A | 1 |
| Rocha, R | 1 |
| Purkayastha, D | 1 |
| Davis, P | 1 |
| Smith, A | 1 |
| DeAngelis, L | 1 |
| Mirenda, V | 1 |
| Kandra, A | 1 |
| Botha, J | 1 |
| Ferber, P | 1 |
| Odum, J | 1 |
| Purkiss, J | 1 |
| Naish, PF | 1 |
| Ljungman, S | 1 |
| Wikstrand, J | 1 |
| Hartford, M | 1 |
| Aurell, M | 1 |
| Lindstedt, G | 1 |
| Berglund, G | 1 |
| Hallab, M | 1 |
| Gallois, Y | 1 |
| Chatellier, G | 1 |
| Rohmer, V | 1 |
| Fressinaud, P | 1 |
| Marre, M | 1 |
| Lacourcière, Y | 3 |
| Nadeau, A | 2 |
| Poirier, L | 2 |
| Tancrède, G | 2 |
| Gin, T | 1 |
| Joon, TL | 1 |
| Cooper, M | 1 |
| Taylor, H | 1 |
| Larochelle, P | 1 |
| Waeber, B | 1 |
| Weidmann, P | 1 |
| Wohler, D | 1 |
| Le Bloch, Y | 1 |
| Yamamoto, M | 1 |
| Fukui, M | 1 |
| Shou, I | 1 |
| Wang, LN | 1 |
| Sekizuka, K | 1 |
| Suzuki, S | 1 |
| Shirato, I | 1 |
| Tomino, Y | 1 |
| Kribben, A | 1 |
| Anlauf, M | 1 |
| Distler, A | 1 |
| Gärtner, H | 1 |
| Holzgreve, H | 1 |
| Michaelis, J | 1 |
| Röcker, L | 1 |
| Schäfers, R | 1 |
| Philipp, U | 1 |
| Wellek, S | 1 |
| Philipp, T | 1 |
| Rachmani, R | 1 |
| Levi, Z | 1 |
| Slavachevsky, I | 1 |
| Half-Onn, E | 1 |
| Ravid, M | 1 |
| Nielsen, S | 1 |
| Dollerup, J | 1 |
| Nielsen, B | 1 |
| Mogensen, CE | 1 |
| Mervaala, E | 1 |
| Müller, DN | 1 |
| Schmidt, F | 1 |
| Park, JK | 1 |
| Gross, V | 1 |
| Bader, M | 1 |
| Breu, V | 1 |
| Ganten, D | 1 |
| Haller, H | 1 |
| Luft, FC | 1 |
| Bélanger, A | 1 |
| Godin, C | 1 |
| Hallé, JP | 1 |
| Ross, S | 1 |
| Wright, N | 1 |
| Marion, J | 1 |
| Lozano, JV | 1 |
| Llisterri, JL | 1 |
| Aznar, J | 1 |
| Redon, J | 2 |
| Fernández, R | 1 |
| Puig, JG | 1 |
| Rodríguez-Pérez, JC | 1 |
| Garrido, J | 2 |
| de Pablos-Velasco, PL | 1 |
| Pazos Toral, F | 1 |
| Esmatjes, JE | 1 |
| Fernandez-Vega, F | 1 |
| Lopez de la Torre, ML | 1 |
| Pozuelo, A | 1 |
| Ruilope, LM | 1 |
| Goicolea, I | 1 |
| Fernández González, R | 1 |
| Piniés, J | 1 |
| Martínez, JM | 1 |
| Armenteros, S | 1 |
| Moreno Carretero, E | 1 |
| Cooper, ME | 1 |
| Rumble, JR | 1 |
| Allen, TJ | 1 |
| O'Brien, RC | 1 |
| Doyle, AE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage[NCT04752293] | 125 participants (Anticipated) | Observational | 2021-05-19 | Recruiting | |||
| A 24-week Study to Evaluate the Effectiveness of Valsartan in Combination With Hydrochlorothiazide Versus Amlodipine on Arterial Compliance in Patients With Hypertension, Type 2 Diabetes and Albuminuria[NCT00171561] | Phase 4 | 144 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Evaluation of Hematologic Patients - Training Protocol[NCT00001715] | 898 participants (Actual) | Observational | 1998-04-21 | Completed | |||
| Effects of Low Sodium Intake on the Anti-proteinuric Efficacy of Olmesartan in Hypertensive Patients With Albuminuria Through Open-label Randomized Trial[NCT01552954] | Phase 4 | 269 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension[NCT00170950] | Phase 3 | 11,506 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.) | ||
| Efficacy and Safety of Two Fixed-combination Antihypertensive Regimens, Amtrel® and Co-Diovan® in Type 2 Diabetes Hypertension Patients With Microalbuminuria[NCT01375322] | Phase 4 | 226 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Aldosterone and Vascular Disease in Diabetes Mellitus[NCT00214825] | 46 participants (Actual) | Interventional | 2003-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Change in albuminuria as a 24-hour urine protein excretion by intensive education of low salt diet during taking olmesartan~*In outcome measure data table, the 24-hour urine collection at 16th week was omitted in 3 out of 245 patients (1 for intensive education group and 2 for conventional education group). Values of each study week were mean of all participants on specific study week, but ∆albuminuria (week 8 - week 16) value was mean of ∆ values of 8 weeks-16 weeks in each individuals. Therefore, values of 3 patients were excluded in mean of ∆albuminuria (week 8 - week 16). That's why simple subtraction (week 8 - week 16) of values are not matched with the data." (NCT01552954)
Timeframe: changes from week 8 at week 16 (week 8 - week 16)
| Intervention | mg/day (Mean) | ||
|---|---|---|---|
| 24hr-urine albumin (8th week) | 24hr-urine albumin (16th week);n=124, 118 | Mean of ∆albuminuria (week 8-week 16); n=124, 118 | |
| Conventional Education of Low-salt Diet Group | 483.5 | 487.3 | -0.4 |
| Intensive Education of Low-salt Diet Group | 569.9 | 417.4 | 154.0 |
The change of hemoglobin after prescription of Olmesartan (NCT01552954)
Timeframe: 0 week, 16 weeks
| Intervention | g/dL (Mean) | |||
|---|---|---|---|---|
| Hemoglobin (week 0) | Hemoglobin (week 8) | Hemoglobin (week 16) | Hemoglobin changes from week 0 at week 16 | |
| Conventional Education of Low-salt Diet Group | 13.8 | 13.5 | 13.3 | 0.46 |
| Intensive Education of Low-salt Diet Group | 14.0 | 13.7 | 13.4 | 0.62 |
Change of sodium excretion rate in 24 hour-urine collection by intensive education for low salt diet at week 16 (NCT01552954)
Timeframe: week 8 and week 16
| Intervention | mEq/day (Mean) | ||
|---|---|---|---|
| week 8 | week 16; n=124, 118 | ∆Na excretion (week 8 - week 16);n=124, 118 | |
| Conventional Education of Low-salt Diet Group | 155.5 | 147.1 | 9.0 |
| Intensive Education of Low-salt Diet Group | 157.4 | 122.1 | 35.4 |
Change in Systolic and Diastolic Blood Pressure from Week 8 to Week 16 in the Intensive Education Group compared to the Conventional Education Group (NCT01552954)
Timeframe: week 8 and week 16
| Intervention | mm Hg (Mean) | |||||
|---|---|---|---|---|---|---|
| Systolic BP at week 8 | Systolic BP at week 16 | sBP changes from week 8 at week 16 | Diastolic BP at week 8 | Diastolic BP at week 16 | dBP changes from week 8 at week 16 | |
| Conventional Education of Low-salt Diet Group | 121.8 | 121.2 | 0.6 | 73.4 | 74.8 | -0.7 |
| Intensive Education of Low-salt Diet Group | 122.1 | 120.4 | 1.7 | 73.6 | 73.1 | 0.5 |
CV mortality was defined as death due to sudden cardiac death, fatal MI, fatal stroke, coronary intervention, congestive heart failure (CHF), or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV mortality event, MI (non-fatal), or stroke (non-fatal) (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 5.0 |
| Benazepril/Hydrochlorothiazide | 6.3 |
Cardiovascular morbidity was defined as including any of the following events: non-fatal MI, non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure (PCI or CABG). (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])]
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 8.6 |
| Benazepril/Hydrochlorothiazide | 10.3 |
CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity or mortality event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an event (Number) |
|---|---|
| Benazepril/Amlodipine | 9.6 |
| Benazepril/Hydrochlorothiazide | 11.8 |
38 trials available for hydrochlorothiazide and Albuminuria
| Article | Year |
|---|---|
The effect of amiloride in decreasing albuminuria in patients with diabetic kidney diseases: a prospective, crossover, open-label study.
Topics: Aged; Albuminuria; Amiloride; Creatinine; Cross-Over Studies; Diabetic Nephropathies; Drug Combinati | 2021 |
Reduction in morning blood pressure is a key factor for ameliorating urinary albumin excretion in patients with morning hypertension irrespective of treatment regimen.
Topics: Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen | 2013 |
Which is a better treatment for hypertensive patients with diabetes: a combination of losartan and hydrochlorothiazide or a maximum dose of losartan?
Topics: Aged; Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2013 |
Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension.
Topics: Adolescent; Adult; Aged; Albuminuria; Antihypertensive Agents; Asian People; Biphenyl Compounds; Blo | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria.
Topics: Adult; Aged; Albuminuria; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agent | 2014 |
Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial.
Topics: Aged; Albuminuria; Blood Pressure; Diabetic Neuropathies; Diet, Sodium-Restricted; Diuretics; Double | 2014 |
Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in Renin-Angiotensin System (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics Tr
Topics: Adult; Aged; Albuminuria; Amlodipine; Blood Pressure; Dihydropyridines; Female; Glomerular Filtratio | 2014 |
Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Ty | 2009 |
Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles | 2009 |
Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension.
Topics: Adult; Albuminuria; Aldosterone; Antihypertensive Agents; Asian People; Blood Pressure; Cross-Over S | 2009 |
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Be | 2010 |
Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.
Topics: Aged; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diab | 2010 |
Losartan/hydrochlorothiazide combination vs. high-dose losartan in patients with morning hypertension--a prospective, randomized, open-labeled, parallel-group, multicenter trial.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Drug Therapy, Combination; Female; Hu | 2012 |
Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando
Topics: Aged; Albuminuria; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiot | 2012 |
[Co-renitek treatment of patients with moderate and severe forms of hypertensive disease].
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2003 |
Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; A | 2005 |
[IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen | 2003 |
Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized c
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetes Mell | 2005 |
The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensi | 2005 |
[Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compou | 2005 |
[Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2004 |
Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Brachia | 2007 |
Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2007 |
Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; A | 2008 |
Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; An | 2008 |
Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes.
Topics: Adolescent; Adult; Albuminuria; Diabetes Mellitus, Type 1; Double-Blind Method; Enalapril; Female; H | 1993 |
Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis.
Topics: Aged; Albuminuria; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Doub | 1993 |
Effect of quinapril on the albumin excretion rate in patients with mild to moderate essential hypertension. Multicenter Study Group.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diur | 1996 |
Hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment. Influence on LVH, proteinuria and metabolic parameters. The HANE Trial Research Group.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Ant | 1997 |
Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; An | 1998 |
Combination of enalapril and low-dose thiazide reduces normoalbuminuria in essential hypertension.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Creatinine; Diuretics; Double | 1998 |
Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Neph | 2000 |
Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics.
Topics: Albuminuria; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, | 2001 |
Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study.
Topics: Aged; Albuminuria; Analysis of Variance; Antihypertensive Agents; Diabetes Mellitus, Type 2; Double- | 2001 |
Losartan titration versus diuretic combination in type 2 diabetic patients.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Mellit | 2002 |
[Effect of antihypertensive combinations on arterial pressure, albuminuria, and glycemic control in patients with type II diabetic nephropathy: a randomized study].
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antih | 2002 |
Comparative effects of converting enzyme inhibition and conventional therapy in hypertensive non-insulin dependent diabetics with normal renal function.
Topics: Aged; Albuminuria; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; Double-Blind Method; Drug T | 1991 |
17 other studies available for hydrochlorothiazide and Albuminuria
| Article | Year |
|---|---|
Regression of albuminuria and hypertension and arrest of severe renal injury by a losartan-hydrochlorothiazide association in a model of very advanced nephropathy.
Topics: Acute Kidney Injury; Albuminuria; Aldosterone; Animals; Antihypertensive Agents; Drug Therapy, Combi | 2013 |
Release from glomerular overload by the addition of low-dose thiazide in patients with angiotensin receptor blocker-resistant hypertension.
Topics: Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Dose-Response Relatio | 2013 |
Salt, hypertension, and proteinuria in diabetic nephropathy.
Topics: Albuminuria; Diabetic Neuropathies; Diet, Sodium-Restricted; Diuretics; Female; Humans; Hydrochlorot | 2014 |
An association of losartan-hydrochlorothiazide, but not losartan-furosemide, completely arrests progressive injury in the remnant kidney.
Topics: Albuminuria; Animals; Blood Pressure; Drug Combinations; Furosemide; Hydrochlorothiazide; Hypertensi | 2016 |
Reduction of albuminuria with antihypertensive treatment: is more always better?
Topics: Albuminuria; Antihypertensive Agents; Azetidinecarboxylic Acid; Dihydropyridines; Humans; Hydrochlor | 2011 |
Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats.
Topics: Albuminuria; Amides; Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus | 2012 |
Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Glucos | 2012 |
[Observational study of blood pressure control and microalbuminuria in type 2 diabetics on Irbesartan or Irbesartan/HCTZ].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2005 |
Impaired fibrinolytic activity in type II diabetes: correlation with urinary albumin excretion and progression of renal disease.
Topics: Aged; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cohort Studies; Creat | 2006 |
[Microalbuminuria in patients with hypertension and cardiovascular comorbidity, REAL observational study of treatment with Irbesartan/HCTZ].
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compo | 2006 |
Influence of differing classes of antihypertensive agents on mesangial kinetics following partial renal ablation in rats.
Topics: Albuminuria; Animals; Antihypertensive Agents; Biological Transport, Active; Enalapril; Glomerular M | 1994 |
Effects of long-term antihypertensive treatment and aging on renal function and albumin excretion in primary hypertension.
Topics: Aging; Albuminuria; Case-Control Studies; Drug Therapy, Combination; Follow-Up Studies; Glomerular F | 1993 |
Organ specificity of antihypertensive therapy on ocular albumin vascular clearance and albuminuria in the hypertensive diabetic rat.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Press | 1996 |
Albuminuria in diabetes mellitus: relation to ambulatory versus office blood pressure and effects of cilazapril.
Topics: Adolescent; Adult; Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pr | 1996 |
Effects of treatment with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor antagonist (AIIRA) on renal function and glomerular injury in subtotal nephrectomized rats.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Bl | 1997 |
Blood pressure-independent effects in rats with human renin and angiotensinogen genes.
Topics: Albuminuria; Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified; Antihypertensi | 2000 |
Antihypertensive therapy in a model combining spontaneous hypertension with diabetes.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Gluco | 1992 |